Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies

• Príomhchruthaitheoirí: Eric L. Simpson (Údar), Leon Kircik (Údar), Andrew Blauvelt (Údar), Howard Kallender (Údar), Daniel Sturm (Údar), Mingyue Wang (Údar), Lawrence F. Eichenfield (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Abstract Introduction Standard therapy for patients with mild to moderate atopic dermatitis (AD) typically includes topical therapies; however, patients with more extensive AD and/or AD refractory to topical therapy may benefit from systemic treatment. Ruxolitinib cream monotherapy has demonstrated...